Akers Biosciences, Inc. (NASDAQ: AKER)

Rowley Law PLLC is investigating potential securities law violations by Akers Biosciences, Inc. (NASDAQ: AKER) and its board of directors concerning the proposed merger of the company with MyMD Pharmaceuticals, Inc. Akers Biosciences stockholders will own 20% of the combined company. The transaction is expected to close in the first half of 2021.

If you are a stockholder of Akers Biosciences, Inc. and are interested in obtaining additional information regarding this investigation, please fill in the contact form on this page. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).

Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Request Information

The submission of this form does not create an attorney-client relationship.

2020-11-12T19:10:07+00:00